SIRPA and neoplasm: These results support the combined use of CD47/SIRPα inhibitors and T-cell immune checkpoint inhibitors, such as PD-1/PD-L1 and TIM-3 inhibitors, to further enhance anti-tumor responses, which has been demonstrated in clinical trials conducted in patients with advanced solid tumors [106].